La vendita allo scoperto per Diversified Healthcare dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Diversified Healthcare. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Diversified Healthcare (NASDAQ:DHC) Azioni, Report sulle vendite allo scoperto

Diversified Healthcare

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs.

Diversified Healthcare Trust - Common Shares of Beneficial Interest

Diversified Healthcare Trust

DHC ACQUISITION CORP UNIT 1 CL A & 1/3 WT EXP

DIAMONDHEAD CASINO CORP by Diamondhead Casino Corp.

Diamondhead Casino Corp

DATA HORIZON CO LTD by DATA HORIZON CO LTD.

Diversified Healthcare Trust - 5.625% Senior Notes due 2042

Diversified Healthcare Trust - 6.25% Senior Notes Due 2046

News

Trading Ideas

BCAB

Scion Asset Management 13F Shows Exited Position In Hudson Pacific Properties, Previously Holding 1,144,435 Shares; Exited Position In BioAtla, Previously Holding 633,959 Shares

Cronos group CEO Mike Gorenstein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) says the cannabis industry should not rely solely on Democratic leadership for reform.
Instead, he says President-elect Donald Trump is personally more open to cannabis reform than Biden, but warned against expecting rapid changes, as cannabis won&#8217;t be a top priority for the new administration.
<h3 class="wp-block-heading">Trump vs. Biden: Cannabis Reform Expectations</h3>
In a recent appearance on Cultivated with Jay Rosenthal via X (formerly Twitter), Gorenstein shared his views on the political landscape following the November elections.
Despite <a href="https://www.benzinga.com/markets/cannabis/24/11/41855573/cannabis-stocks-plunged-after-florida-legalization-failed-rational-reaction-or-market-overreach">poor market response</a> to the results, Gorenstein remains optimistic. He pointed out the successes in red and purple states while acknowledging that traditional blue-state markets like California and Massachusetts are not the best examples of cannabis markets.
In the midst of the expectations created by Trump&#8217;s<a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation"> </a><a href="https://www.benzinga.com/news/legal/24/11/41959036/trump-nominates-another-cannabis-supporter-to-cabinet-rep-matt-gaetz-for-attorney-general">nomination</a> of cannabis legalization supporter Matt Gaetz to his cabinet, Gorenstein advised caution about expecting significant changes in the near future, pointing out that while Trump might be more favorable, cannabis is unlikely to be a top priority for incoming administration.
"As far as timing, you can&#8217;t expect it to happen next year. There's a lot of things that need to be done, and it's not the primary issue," he added.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41904096/cronos-cannabis-co-reports-38-yoy-increase-in-q3-revenue-boosts-international-sales">Trump Nominates Another Cannabis Supporter To Cabinet: Rep. Matt Gaetz For Attorney General</a>
<h3 class="wp-block-heading">Focusing on Strategy, Not Stock Prices</h3>
Discussing Cronos&#8217; approach, Gorenstein said the company does not need to issue more shares. Instead they are focusing on building a strong portfolio of high-quality cannabis products and expanding to global markets such as <a href="https://www.benzinga.com/topic/germany-cannabis">Germany</a>.
The company is going through a good moment that reflects in the fact they are running low on product, and needing to invest on escalation of their current operations to catch up with the growing demand.
Still, prices cannabis stocks have been on a <a href="https://www.benzinga.com/markets/cannabis/24/11/41793174/cannabis-stocks-collapse-after-trump-win-major-players-see-double-digit-declines-at-wednesdays-c">downtrend</a>, but for Gorenstein, &#8220;you just get used to volatility&#8230; it's a real mistake and a trap to follow stocks every day."
<h3 class="wp-block-heading">Earnings Report Q3 2024</h3>
Recently Cronos Group <a href="https://www.benzinga.com/news/earnings/24/11/41904096/cronos-cannabis-co-reports-38-yoy-increase-in-q3-revenue-boosts-international-sales">reported</a> Q3 2024 net revenue of $34.3 million, a 38% increase driven by stronger cannabis sales across Canada, Israel, and international markets. 
Despite a net income turnaround to $7.3 million, adjusted EBITDA remained negative at $6 million.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39418098/cronos-cannabis-co-will-provide-51m-to-growco-toward-facility-expansion-fund">Cronos Cannabis Co. Will Provide $51M To GrowCo Toward Facility Expansion Fund</a></li>
</ul>
COVER: <a href="https://unsplash.com/@kiffen?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">GRAS GRÜN</a>&nbsp;on&nbsp;<a href="https://unsplash.com/photos/ground-cannabis-on-clear-plastic-bag-iCHacuW8BcI?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Unsplash</a><a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Cannabis

Markets

Media

CRON

Cronos CEO Mike Gorenstein Says He's Optimistic About Trump's Impact On Cannabis

Whales with a lot of money to spend have taken a noticeably bearish stance on Citigroup.
Looking at options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) we detected 22 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 59% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $211,613 and 17, calls, for a total amount of $732,862.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $90.0 for Citigroup over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Citigroup stands at 14385.71, with a total volume reaching 32,890.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Citigroup, situated within the strike price corridor from $50.0 to $90.0, throughout the last 30 days.
<h3>Citigroup Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731612791_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.29</td>
<td>$1.26</td>
<td>$1.26</td>
<td>$70.00</td>
<td>$74.5K</td>
<td>14.5K</td>
<td>1.6K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.0</td>
<td>$4.95</td>
<td>$5.0</td>
<td>$65.00</td>
<td>$62.0K</td>
<td>16.3K</td>
<td>159</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$20.6</td>
<td>$20.2</td>
<td>$20.2</td>
<td>$50.00</td>
<td>$60.6K</td>
<td>4.3K</td>
<td>30</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.78</td>
<td>$2.74</td>
<td>$2.74</td>
<td>$70.00</td>
<td>$58.9K</td>
<td>73.6K</td>
<td>231</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.53</td>
<td>$1.52</td>
<td>$1.52</td>
<td>$72.50</td>
<td>$55.6K</td>
<td>28.1K</td>
<td>2.3K</td>
</tr>
</tbody>
</table>

<h3>About Citigroup</h3>
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
Having examined the options trading patterns of Citigroup, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Citigroup's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 9,127,274, the C's price is down by -1.34%, now at $67.97. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>Expert Opinions on Citigroup</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $82.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Citigroup, targeting a price of $107. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their In-Line rating on Citigroup, which currently sits at a price target of $64. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Citigroup, which currently sits at a price target of $82. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Citigroup, which currently sits at a price target of $91. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Citigroup, maintaining a target price of $70. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Citigroup options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Citigroup's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IREN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 25 uncommon options trades for Iris Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 24% bullish and 76%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $363,576, and 18 are calls, for a total amount of $1,432,624.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $7.5 and $25.0 for Iris Energy, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Iris Energy stands at 9568.85, with a total volume reaching 24,574.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Iris Energy, situated within the strike price corridor from $7.5 to $25.0, throughout the last 30 days.
<h3>Iris Energy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731612786_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.9</td>
<td>$3.7</td>
<td>$3.72</td>
<td>$8.00</td>
<td>$354.1K</td>
<td>4.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.8</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$10.00</td>
<td>$164.3K</td>
<td>6.1K</td>
<td>686</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.95</td>
<td>$2.9</td>
<td>$2.9</td>
<td>$12.00</td>
<td>$162.1K</td>
<td>7.4K</td>
<td>1.8K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$1.7</td>
<td>$1.6</td>
<td>$1.62</td>
<td>$11.50</td>
<td>$121.5K</td>
<td>261</td>
<td>750</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.4</td>
<td>$3.3</td>
<td>$3.4</td>
<td>$12.50</td>
<td>$90.1K</td>
<td>38.9K</td>
<td>913</td>
</tr>
</tbody>
</table>

<h3>About Iris Energy</h3>
Iris Energy Ltd is a Bitcoin mining company. It builds, owns, and operates data centers and electrical infrastructure for the mining of Bitcoin powered by renewable energy. The company's mining operations generate revenue by earning Bitcoin through a combination of block rewards and transaction fees from the operation of its specialized computers called Application-specific Integrated Circuits and exchanging these Bitcoin for currencies such as USD or CAD on a daily basis.
Following our analysis of the options activities associated with Iris Energy, we pivot to a closer look at the company's own performance.
<h3>Where Is Iris Energy Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 13,425,692, with IREN's price down by -4.09%, positioned at $10.44.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 12 days.</li>
</ul>
<h3>Professional Analyst Ratings for Iris Energy</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $20.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $20.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Iris Energy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

IREN

Iris Energy's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bullish move on Intel. Our analysis of options history for Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) revealed 31 unusual trades.
Delving into the details, we found 54% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $257,224, and 25 were calls, valued at $1,795,747.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $40.0 for Intel over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Intel's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Intel's whale trades within a strike price range from $13.0 to $40.0 in the last 30 days. 
<h3>Intel Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731612781_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.25</td>
<td>$1.2</td>
<td>$1.22</td>
<td>$35.00</td>
<td>$366.0K</td>
<td>17.3K</td>
<td>5.1K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.85</td>
<td>$7.75</td>
<td>$7.75</td>
<td>$25.00</td>
<td>$279.0K</td>
<td>4.1K</td>
<td>363</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.22</td>
<td>$0.2</td>
<td>$0.21</td>
<td>$31.00</td>
<td>$210.9K</td>
<td>6.4K</td>
<td>14.7K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.19</td>
<td>$0.18</td>
<td>$0.19</td>
<td>$31.00</td>
<td>$133.8K</td>
<td>6.4K</td>
<td>7.7K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.8</td>
<td>$9.75</td>
<td>$9.8</td>
<td>$18.00</td>
<td>$98.0K</td>
<td>8.6K</td>
<td>106</td>
</tr>
</tbody>
</table>

<h3>About Intel</h3>
Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.
In light of the recent options history for Intel, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Intel Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 26,741,593, with INTC's price up by 0.82%, positioned at $25.12.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 70 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intel with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

INTC

Smart Money Is Betting Big In INTC Options

60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.70) by 32.86 percent. The company reported quarterly sales of $135.00 thousand which missed the analyst consensus estimate of $242.00 thousand by 44.21 percent. This is a 163.73 percent increase over sales of $51.19 thousand the same period last year.

Earnings

Earnings Misses

SXTP

60 Degrees Q3 2024 GAAP EPS $(0.93) Misses $(0.70) Estimate, Sales $135.00K Miss $242.00K Estimate

BABA

BIDU

FOUR

OLPX

Scion Asset Management 13F Shows Increased Stake In Alibaba Group From 155,000 To 200,000 Shares; Increased Stake In JD.com From 250,000 To 500,000 Shares;  Increased Stake In Shift4 Payments From 100,000 To 150,000 Shares; Increased Stake In Baidu From 75,000 To 125,000 Shares; Increased Stake In Molina Healthcare From 24,530 To 30,000 Shares; Increased Stake In Olaplex Holdings From 995,250 To 1,000,000 Shares

Scion Asset Management 13F Shows Added Put Position In JD.com With 500,000 Shares; Added Put Position In Alibaba Group With 168,900 Shares; Added Put Position In Baidu With 83,300 Shares

Sony Group Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) November 2024 PlayStation Plus Game Catalog lineup offers a mix of popular titles and classic <a href="https://www.benzinga.com/general/gaming">games for subscribers. </a>
Take-Two Interactive Software Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) Grand Theft Auto V leads this month's selection, marking the game's return to the service. Alongside it, Dying Light 2: Stay Human and Like a Dragon: Ishin will also be available from Nov. 19, PlayStation <a href="https://blog.playstation.com/2024/11/13/playstation-plus-game-catalog-for-november-grand-theft-auto-v-dying-light-2-stay-human-like-a-dragon-ishin-and-more/">announced </a>in a blog post.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41884190/did-rockstar-drop-gta-6-trailer-hint-fans-spot-moon-clue-pointing-to-nov-22">Did Rockstar Drop GTA 6 Trailer Hint? Fans Spot Moon Clue Pointing To Nov. 22</a>
Premium members gain access to PS VR2's Synapse and four Classic titles, including Blood Omen: Legacy of Kain, Blood Omen 2, Resistance: Fall of Man, and Resistance 2, the latter two available only via streaming. With Soul Reaver 1 &amp; 2 Remastered arriving next month, the addition of these titles may appeal to fans of older franchises and offer a touch of nostalgia for longtime PlayStation players.
Here's a full rundown of the PlayStation Plus Game Catalog for November 2024:
<h3 class="wp-block-heading">PlayStation Plus Extra and Premium &#x7C; Game Catalog</h3>
<ul>
<li>Grand Theft Auto V &#x7C; PS4, PS5</li>
<li>Dying Light 2: Stay Human &#x7C; PS4, PS5</li>
<li>Like a Dragon: Ishin &#x7C; PS4, PS5</li>
<li>MotoGP 24 &#x7C; PS4, PS5</li>
<li>The Sims 4 Island Living (add-on only) &#x7C; PS4</li>
<li>Digimon Survive &#x7C; PS4</li>
<li>Overcooked! All You Can Eat &#x7C; PS4, PS5</li>
<li>Stick Fight: The Game &#x7C; PS4</li>
<li>Clash: Artifacts of Chaos &#x7C; PS4, PS5</li>
<li>Killer Frequency &#x7C; PS4, PS5</li>
<li>Hungry Shark World &#x7C; PS4</li>
<li>Chivalry 2 &#x7C; PS4, PS5</li>
</ul>
<h3 class="wp-block-heading">PlayStation Plus Premium</h3>
<ul>
<li>Synapse &#x7C; PS VR2</li>
<li>Blood Omen: Legacy of Kain &#x7C; PS4, PS5</li>
<li>Blood Omen 2 &#x7C; PS4, PS5</li>
<li>Resistance: Fall of Man (streaming only)</li>
<li>Resistance 2 (streaming only)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41948549/xbox-handheld-a-few-years-out-says-microsoft-gaming-ceo-hints-at-cross-platform-games-new-acquisitions">Xbox Handheld &#8216;A Few Years Out,&#8217; Says Microsoft Gaming CEO; Hints At Cross-Platform Games, New Acquisitions</a></li>
</ul>
Image courtesy: PlayStation.

Gaming

General

Sony Group Corporation American Depositary Shares

SONY

TTWO

GTA 5 Joins November's PlayStation Plus Lineup With Other Fan-Favorites

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock is moving lower on continued weakness Thursday after the company filed a FormNT 10-Q with the Securities and Exchange Commission, indicating that it&#8217;s unable to file its 2025 fiscal-year first-quarter earnings <a href="https://www.benzinga.com//node/41938588">on time</a>.
The Details: Super Micro Computer said that it cannot complete and file its quarterly earnings before it finishes its 2024 fiscal-year earnings. Previously, the company told the SEC that it could not file its 2024 fiscal-year earnings on time.
In addition, the company is still selecting a new independent accounting firm after its previous accounting firm, Ernest &amp; Young, resigned. Allegedly, Ernest &amp; Young resigned due to accounting issues and export control violations.
The resignation of the company&#8217;s auditor puts Super Micro at risk of being delisted. If the company is delisted, it may be required to repay as much as $1.725 billion in convertible bonds ahead of schedule.
The new accounting firm will need time to review the company&#8217;s financial statements and its internal controls. Additionally, Super Micro&#8217;s management team is still assessing the effectiveness of the company&#8217;s internal controls.
How To Buy Super Micro Computer Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Super Micro Computer's case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/24/11/41936392/whats-going-on-with-palantir-stock-after-renewing-collaboration-with-rio-tinto">What&#8217;s Going On With Palantir Stock After Renewing Collaboration With Rio Tinto?</a>
SMCI Price Action: At the time of publication, Super Micro stock is trading 8.44% lower at $18.62, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

SMCI

What's Going On With Super Micro Computer Shares Thursday?

WIIM

Jackson Financial shares are trading lower after Evercore ISI Group downgraded the stock from In-Line to Underperform.

On Wednesday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41957228/treatment-with-tirzepatide-in-adults-with-pre-diabetes-and-obesity-or-overweight-resulted-in-susta" rel="noreferrer noopener">date of tirzepatide</a>.
Weekly tirzepatide (Zepbound and Mounjaro) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" rel="noreferrer noopener">over 176 weeks</a>.
Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period for the efficacy estimandi.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks</a>
&#8220;Individuals treated with tirzepatide lost on average up to 23% of their body weight and maintained this for over three years while benefitting from a substantial decrease in risk of developing type 2 diabetes. In absolute terms, nearly 99% of individuals treated with tirzepatide remained diabetes-free at 176 weeks,&#8221; said&nbsp;Ania Jastreboff, director of the Yale Obesity Research Center.
&#8220;In the SURMOUNT-1 three-year study of tirzepatide, an average weight reduction of up to 22.9% was accompanied by a hazard ratio of 0.06 for progression to type 2 diabetes. This translates to a risk reduction of 94% and a number needed to treat of nine to prevent one case of diabetes,&#8221; said&nbsp;Jeff Emmick, SVP of product development at Eli Lilly.
At 193 weeks, 2.4% of patients on Lilly&#8217;s tirzepatide were diagnosed with Type 2 diabetes compared to 13.7% of patients in the placebo group.
In additional endpoints, the study showed an association of tirzepatide treatment with improved glycemic control, cardiometabolic risk factors (including fasting insulin, blood pressure, and lipids), and health-related quality of life sustained through 176 weeks.
A post hoc mediation analysis suggested that approximately half of the observed effect in a delay to onset of type 2 diabetes with tirzepatide was associated with medication-induced weight reduction.
Price Action: LLY stock is down 2.21% at $793.97 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/24/11/41978942/salesforce-ceo-marc-benioff-bets-big-on-billion-bots" target="_blank" rel="noreferrer noopener">Salesforce CEO Marc Benioff Bets Big on Billion Bots</a></li>
</ul>
Image by Mohammed_Al_Ali via Shutterstock

Biotech

Large Cap

Health Care

99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows

Nuvectis Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock is trading lower after the company reported data from the Phase 1b study evaluating NXP800 in patients with platinum-resistant ARID1a-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41967504/nuvectis-pharma-reports-encouraging-nxp800-interim-data-supporting-ongoing-enrollment-in-phase-1b-" rel="noreferrer noopener">mutated ovarian cancer</a>.
Three dosing regimens have been evaluated in twelve patients (four patients were treated on a once-per-day dosing schedule, two with 75 mg/day and two with 50 mg/day.
Subsequently, eight additional patients were treated with 50 mg/day on an intermittent dosing schedule of five days on / two days off, a dosing schedule implemented to mitigate thrombocytopenia).
All patients enrolled into the study failed at least two prior lines of systemic chemotherapy, including at least one prior platinum-based chemotherapy regimen, and most had also failed treatment with bevacizumab.
In eleven efficacy-evaluable patients, antitumor activity was observed with best responses, including one with an unconfirmed partial response and six patients with stable disease, including tumor shrinkage.
The Phase 1b interim data reported earlier this year included four patients evaluable for safety, of which three experienced Grade 4 thrombocytopenia.
Subsequently, in the eight patients treated with NXP800 using the intermittent dosing schedule (50 mg/day, 5 days on / 2 days off), the highest grade of thrombocytopenia observed was Grade 2 (one patient).
Other than thrombocytopenia, the most common treatment emergent adverse events included nausea, fatigue, vomiting, diarrhea and constipation, the majority of which being Grade 1-2.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, said, &#8220;However, it is clear that we need to increase the dose intensity to drive more efficacy in the next set of patients. We are already enrolling patients into a cohort of up to 10-12 additional patients utilizing a regimen of 75 mg/day on an intermittent dosing schedule, which is expected to be the last cohort in this Phase 1b study. We expect to provide additional clinical data from the Phase 1b study in the second quarter of 2025.&#8221;
The NXP800 development program for this disease was granted FDA Fast Track Designation, and NXP800 was granted FDA Orphan Drug Designation for ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
Price Action: NVCT stock is down 43.20% at $6.05 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41977961/mastercards-vision-no-more-passwords-or-card-numbers-by-2030" target="_blank" rel="noreferrer noopener">Mastercard&#8217;s 2030 Vision: A Future Without Passwords, Card Numbers</a></li>
</ul>

NVCT

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

In a costly error, an anonymous cryptocurrency investor known as &#8220;qklpjeth&#8221; recently lost $25 million after mistakenly transferring funds to an inaccessible contract address, prompting the investor to emphasize the relative safety <a href="https://www.benzinga.com/money/what-is-a-crypto-exchange">of centralized exchanges</a>.
What Happened: "Staking on centralized exchanges feels more secure since on-chain staking still carries significant risks," qklpjeth told Benzinga.
The misstep occurred on June 19, when 7,912.31 ezETH, a restaked Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) token issued by the Renzo protocol, was accidentally sent to the wrong address.
The user explained that a simple error in copying and pasting an address resulted in the funds being locked away permanently. 
&#8220;The funds were sent to a contract address that cannot be accessed,&#8221; said qklpjeth, adding that "the error happened simply because the wrong address was copied." 
Despite months of attempts to contact Renzo protocol for assistance, no progress has been made. 
The investor even issued a public appeal, offering a 10% reward, or $2.5 million, to anyone who could help recover the locked funds.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41984505/bitcoin-to-peak-at-180000-says-vanecks-head-of-digital-assets-research">Bitcoin To Peak At $180,000, Says VanEck&#8217;s Head Of Digital Assets Research</a>
Why It Matters: The irreversible nature of such errors in the DeFi space has drawn the attention of industry experts.
Speaking with Benzinga, Ido Ben-Natan, co-founder &amp; CEO of Blockaid, points out that this incident underscores the dangers users face when they aren't fully aware of transaction details. 
"This is an unfortunate incident which highlights one of the core issues of modern-day crypto," Ben-Natan noted. "More often than not, users are unaware of the full ramifications of the transactions they sign." 
According to Ben-Natan, mistakes like these, which can include address typos or unintentional protocol misuses, occur because users often don't understand the complete impact of their transactions. 
While solutions to these issues exist, they are still limited. 
"Due to the very nature of crypto, in many cases it is impossible to revert an action," he explained. 
This, Ben-Natan emphasized, is why "users must take extra precautions, especially when moving large amounts of assets."
Echoing Ben-Natan's concerns, Ogle, CEO of Glue, elaborated on the technical complexities that can lead to such errors, specifically citing address discrepancies across blockchain networks. 
"Contract addresses vary across different blockchain networks, even when using the same underlying code," he said, adding that users often mistakenly copy a contract address from one network to another, leading to failed transactions. 
Ogle further advised that, until better user interfaces are developed, users should be cautious, especially when conducting large transactions. 
&#8220;The key is verifying both the network and address before any transaction,&#8221; he recommended. 
As a precautionary measure, Ogle himself advocates sending small test transactions before transferring significant sums. 
"This complexity shouldn't exist in cryptocurrency," he said. "Ideally, these technical details should be abstracted away, but for now, it's best to remain cautious."
Ogle, CEO of Glue, agreed, noting the complexities that arise from differences in contract addresses across blockchain networks. 
He mentioned that "verifying both the network and address before any transaction" is essential, especially given the current limitations in blockchain's user experience design. 
He also recommended that users take advantage of emerging blockchain safety features and test transactions as a standard practice. 
"Sending a small test amount first can save users from substantial loss. It's just good practice in a system where mistakes can&#8217;t be undone," he told Benzinga.
Asked about improvements within blockchain security that could help minimize the risks of irreversible mistakes like this one in the future, he said there were two approaches to mitigate risks &#8211; Either blockchains can implement emergency measures like network forks &#8211; similar to how Ethereum split into Ethereum and Ethereum Classic years ago.
He added that a more practical approach is improving user experience through better safety features. 
&#8220;Think text message confirmations (2FA), prompts to verify the network you&#8217;re on, checks on transaction amounts, and reminders to do test transactions first,&#8221; he said,
What&#8217;s Next: Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 may shed further light on issues like these, with stakeholders likely discussing best practices and tools to enhance user safety in the rapidly evolving world of digital finance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41980737/bitcoin-is-here-to-stay-poised-for-significant-growth-says-former-td-ameritrade-ceo-joe-moglia">&#8216;Bitcoin Is Here To Stay, Poised For Significant Growth,&#8217; Says Former TD Ameritrade CEO Joe Moglia</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

Investor Loses $25M Due To Misplaced Crypto Transfer, Says CEXs Feel More Secure

Helmerich & Payne shares are trading lower after the company reported worse-than-expected Q4 financial results.

Hillenbrand shares are trading higher. Keybanc maintained an Overweight rating on the stock

Piper Sandler analyst Michael S. Lavery upgraded Campbell Soup Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) to Overweight from Neutral, <a target="_blank" href="https://www.benzinga.com/quote/CPB/analyst-ratings" rel="noreferrer noopener">raising the price forecast from $47 to $56.</a>
The analyst upgraded Campbell Soup due to improved long-term growth prospects from its Rao&#8217;s brand and better sales trends in the U.S. (excluding SOVO brands).
Despite better trends, the stock has had a 15% pullback since mid-September. The analyst sees this as a good buying opportunity.
Lower steel costs (down 25%) and secured contracts for 2025 further support growth.
The analyst raised 2025 and 2026 earnings per share (EPS) estimates slightly, from $3.20 to $3.21 and $3.37 to $3.38, respectively.
Per the analyst, the stock is considered well-positioned among large-cap food stocks.
Also Read:<a target="_blank" href="https://benzinga.com/trading-ideas/movers/24/11/41982273/whats-going-on-with-ford-motor-stock-today-4" rel="noreferrer noopener"> What&#8217;s Going On With Ford Motor Stock Today?</a>
Campbell Soup has agreed to sell its Noosa yogurt business for an undisclosed amount, with the deal expected to close in first quarter of 2025. The company acquired Noosa as part of its SOVO purchase in March 2024.
The analyst assumes the sale will be finalized on January 1, 2025, with proceeds of around $250 million.
Per the analyst, the divestiture is expected to reduce sales by approximately $177 million annually and will slightly lower F25 earnings per share (EPS) by $0.01.
However, this impact is expected to be more than offset by higher revenue growth expectations.
The analyst raised the 2025 EPS estimates from $3.20 to $3.21 and the 2026 EPS expectations from $3.37 to $3.38.
Price Action: CPB shares are trading higher by 1.16% to $44.79 at last check Thursday.
Photo via <a href="https://commons.wikimedia.org/wiki/File:Campbell_tomato_soup_cans.jpg">Wikimedia Commons</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine" target="_blank" rel="noreferrer noopener">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a></li>
</ul>

Analyst Color

Equities

Upgrades

Price Target

Analyst Ratings

Campbell Soup Rao's Brand Growth Strong And US Sales Trend Improving, Analyst Upgrades Stock

Goldman Sachs analyst Mark Delaney maintained a neutral rating on Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and raised the price target from&nbsp;$10&nbsp;to&nbsp;$12.
Following the market close on November 12, 2024, Rivian Automotive and Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) confirmed <a target="_blank" href="https://www.benzinga.com/24/11/41934150/rivian-shares-rise-13-in-pre-market-after-volkswagen-increases-planned-investment-to-58b" rel="noreferrer noopener">the official launch</a> of their 50-50 joint venture (JV), set to begin on November 13.
The JV will focus on advancing electrical and electronic (E/E) architecture technology, explicitly targeting electronic control units (ECUs), network infrastructure, and associated software.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41973754/bilibilis-q3-earnings-revenue-surges-26-record-user-growth-margins-improve-as-games-lead-the-way" rel="noreferrer noopener">Bilibili's Q3 Earnings: Revenue Surges As Games Lead the Way, Stock Buyback And More</a>
Both companies will continue to develop vehicles independently, excluding areas like battery technology, powertrains, and autonomous driving systems from the collaboration.
The JV plans to leverage Rivian's existing software and E/E architecture stack. Rivian's R2 model, slated for production in the first half of 2026, will be the first vehicle to utilize this platform, with Volkswagen expected to implement it in their vehicles by 2027. An initial demonstration model, a retrofitted VW vehicle showcasing Rivian's technology, has already been developed as part of this collaboration.
The JV agreement outlines an increased total investment of up to $5.8 billion by 2027, revised upward from the initial $5 billion. Rivian's Chief Software Officer, Wassym Bensaid, and Volkswagen's Chief Technology Engineer, Carsten Helbing, will lead the initiative.
Although both companies will contribute staff, Rivian will initially provide most personnel.
Rivian received $1 billion through a convertible note at the JV's inception. With the JV now operational, Volkswagen has committed an additional $1.3 billion to Rivian for background IP licenses and a 50% equity stake.
The remaining investment, up to $3.5 billion, will be contingent on achieving specific milestones: $1 billion linked to financial performance, $1.5 billion tied to technical and operational benchmarks, and $1 billion structured as loans with time-based disbursements.
Under the agreement, through 2028, Rivian will cover 25% of shared platform costs, while Volkswagen will handle 75%. Starting in 2029, the partners will split expenses evenly, with Volkswagen providing an extra $100 million annually to reduce Rivian's financial burden.
Rivian expects the capital from Volkswagen and its existing liquidity to be sufficient to support operations through the production ramp of the R2 model in Normal, Illinois, and future midsize platforms in Georgia.
Analyst Delaney views the joint venture as a positive development for Rivian, significantly improving its balance sheet and liquidity without additional stock dilution.
Delaney stated that the deal highlights the strategic value of Rivian's technology platform, particularly in software and services, as emphasized in the recent "Platforms &amp; Power" report.
Despite these positives, the analyst maintains a Neutral rating on Rivian shares, citing a challenging competitive landscape, uncertainties around EV demand, and policy risks in the U.S. market.
Following the announcement, Delaney updated his financial estimates for Rivian, accounting for reduced operating expenses and an adjusted share count balanced against expected equity method losses from the JV.
The revised EPS forecasts, including stock-based compensation (SBC), are—$4.49 for 2024,—$3.10 for 2025, and—$3.00 for 2026, reflecting slight improvements from prior estimates. Excluding SBC, the EPS projections stand at—$3.77 for 2024,—$2.35 for 2025, and—$2.20 for 2026.
The analyst also raised Rivian's 12-month price target, citing improved free cash flow and a stronger balance sheet. The valuation now applies a 2.5x multiple on projected Q5-Q8 revenue, up from the previous 2x multiple.
Wedbush analysts, led by Dan Ives, view Volkswagen's increased $5.8 billion investment in Rivian as a <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41938838/rivians-deal-with-volkswagen-will-help-ev-giant-navigate-the-ship-in-stormy-waters-says-top-analyst-maintains-outperform-rating-with-20-target" rel="noreferrer noopener">pivotal boost for</a> the EV maker. They believe the joint venture marks a crucial step toward stabilizing Rivian's finances and enhancing production capabilities.
The partnership aims to strengthen Rivian's capital position, supporting its software and electrical systems integration.
Analysts expect the additional funding to back the R2 production ramp and development at the Georgia facility while the market remains focused on Rivian's execution and profitability goals for the R1 model.
Price Action: RIVN stock is down 11% at $10.71 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41970826/jd-com-q3-earnings-revenue-beats-forecast-amid-consumer-rebound-highlights-supply-chain-strength-eyes-margin-growth" target="_blank" rel="noreferrer noopener">JD.com Q3 Earnings: Revenue Beats Forecast Amid Consumer Rebound, Highlights Supply Chain Strength, Eyes Margin Growth</a></li>
</ul>
Photo by Tada Images on Shutterstock

Reiteration

Tech

RIVN

VWAGY

Rivian-Volkswagen Deal Strengthens Finances, Yet EV Market Risks Remain: Goldman Sachs

Dillard's shares are trading higher after the company reported better-than-expected Q3 EPS results.

22nd Consecutive Year of Increases&nbsp;
ST. LOUIS, Nov. 14, 2024 /PRNewswire/ -- The board of directors of Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) unanimously agreed to increase the annual common stock dividend to $3.14 per share from $3.02 per share. The $0.12 per share increase brings the quarterly rate to $0.785, an increase of 4.0%.

Dividends

Spire Increases Quarterly Common Stock Dividend From $0.7550 To $0.785 Per Share

The State Of REITs: October 2024 Edition

REITs Rally As Earnings Begin

My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 12 Buys

MOBs, Office But No Need For Life Support

Here are the major earnings after the close today

Diversified Healthcare Trust FFO of $0.02 misses by $0.02, revenue of $373.64M misses by $6.53M

Diversified Healthcare: The Baby Bonds Still Look The Most Appealing

Diversified Healthcare Trust (DHC) Q3 2024 Earnings Call Transcript

Diversified Healthcare Trust ( ($DHC) ) has released its Q3 earnings. Here is a breakdown of the information Diversified Healthcare Trust presented...

Diversified Healthcare Trust: Q3 2024 Financial Insights

In a report released today, Aaron Hecht from JMP Securities reiterated a Hold rating on Diversified Healthcare Trust (DHC – Research Report). The c...

Comments

Diversified Healthcare

Vendite allo scoperto

Diversified Healthcare (NASDAQ:DHC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO